Precision Oncology in the Era of Health Care Reform Improving Outcomes, Sustaining Innovation, and Increasing Value
Vice President Biden’s “cancer moonshot” and America’s ongoing debate over oncology-drug affordability have captured national attention. As patients, advocates, and families do battle with cancer, our medical and biotechnology community makes great strides in using patients’ precise biology to better target tumors. Delivering innovative treatments to patients safely, affordably, and effectively requires public policy that rises to the sophistication of our best science. Please join us on Capitol Hill to discuss new frameworks for clinical-data sharing, conditional-drug approvals, and value-based pricing that can help deliver better outcomes to patients and more value to America’s health care system.
| 10:00 - 10:15 AM | Registration & Seating |
| 10:15 - 10:25 AM | Keynote Address: Tom Coburn, Project FDA Advisor, Manhattan Institute |
| 10:25 - 11:30 AM | Advancing Effective and Affordable Precision Oncology Moderator: Paul Howard, Director, Health Policy, Manhattan Institute Amy Abernethy, Chief Medical Officer, Flatiron Health Matt Shaulis, Regional President, Pfizer Oncology North America Elizabeth Thompson, President and CEO, C-Change Mark Trusheim, Visiting Scientist, MIT Sloan |
| 11:30 - 12:00 PM | Q&A |
| 12:00 PM | Lunch |
212-599-7000
communications@manhatan-institute.org